PanOptica

Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient’s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully.

Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.

PanOptica headquartered in United States, North America, operates in the Biotechnology, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $6.6B in funding across 60 round(s). With a team of 101-250 employees, PanOptica is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - PanOptica, raised $30.0M. Discover more about their projects, partnerships, and impact on our platform.